• High resolution touch screen 8,4″
• LCD backup display
• Intuitive user interface

• Intergrated infusion stand
• Automated dual pump control: high pulsatile blood flow
• USB interface: easy data export and fast software update
• Battery charge level indicator

• Connection arterial pressure sensor
• Flow and bubble sensor
• Multifunktional connector (pressure sensors)
• Interface dosing system: rapid volume and drug delivery
• Intergrated venous blood gas analysis (Hb, S_vO₂, T_ven)

• Reperfusion set: preconfigured tubin system, fast priming

• Intergrated arterial blood gas analysis
• Battery compartment for two li-ion batteries: mains independent operation for 3 hours

Ahead-of-the-curve technology.

CARL System. Controlled. Targeted. Personalized.

The CARL System is designed to improve survival and neurologic recovery in patients affected by acute cardiac arrest. The technological performance characteristics of the CARL System components are based on the requirements of CARL Therapy, a novel therapeutic approach for resuscitation that emphasizes controlled, targeted and personalized whole-body reperfusion.

Statement Prof. Dr.-Ing. Benk

“To establish CARL Therapy in clinical practice, numerous innovative approaches in the field of medical technology were required. The visionary challenge was to be able to automatically control both the physical and biochemical perfusion conditions during extracorporeal circulation, both inside and outside the hospital.

We met this challenge - and today we have reached the point where our smart system can start its journey into hospitals.”

Prof. Dr.-Ing. Christoph Benk
Managing Director, Resuscitec GmbH

Controlled Automated Reperfusion of the whole body.

CARL Therapy is a smart method of resuscitation after cardiac arrest. It was developed in an interdisciplinary collaboration between physicians and perfusionists at the Clinic for Cardiovascular Surgery at Freiburg University Hospital.

The new treatment method concerns sudden “acute cardiac arrest”, which until now can only be treated to a very limited extent even under optimal conditions. The survival rate in a hospital is about 20%. And, outside a hospital, only 3 to 8% of all patients survive an acute cardiovascular arrest. In addition, the few patients who leave the hospital often suffer from pronounced and persistent brain damage.

CARL Therapy relies on controlled restoration of blood flow through reperfusion. The Medical Director of Cardiovascular Surgery Freiburg and his team of researchers have discovered that it is thus possible to resuscitate a person even after a prolonged cardiac arrest without significant consequential damage.

Statement Univ.-Prof. Dr. Dr. h. c. Beyersdorf

“After a cardiovascular arrest, the entire body is in a special state that must be understood very precisely and treated individually for each patient. Above all, the patient's blood must be modified in such a way that the organs can gradually recover from the lack of oxygen supply. Based on the findings of our many years of clinical research, we have therefore developed a novel therapy for resuscitation, which we call CARL Therapy.”

Univ.-Prof. Dr. Dr. h. c. Friedhelm Beyersdorf
Founder and Initiator, Resuscitec GmbH
Former Medical Director of the Clinic of Cardiovascular Surgery at The Medical Center - University of Freiburg

Three products, one purpose: Saving lives.

Enabling perfusion technologies.

With CARL, we produce and market the world's first extracorporeal system that can be used to provide sufficient blood circulation in a controlled manner outside the hospital.